TableĀ 4

Adverse events summary of patients with NOMID in a 24-month open-label study of canakinumab

Typen (%)Typen (%)
Ear disordersBlood uric acid decrease2/2 (33.3)
Ear pain2/2 (33.3)C-reactive protein increase5/3 (50)
Gastrointestinal disordersBasophil count increase2/2 (33.3)
Gastrointestinal reflux2/1 (16.7)Eosinophil count increase7/5 (83.3)
General disordersLymphocyte count increase2/2 (33.3)
Pyrexia3/2 (33.3)Monocyte count increase2/1 (33.3)
InfectionsNeutrophil count increase3/2 (33.3)
Ear infection1/1 (16.7)RBC sedimentation rate2/2 (33.3)
Fungal infection1/1 (16.7)WBC count increase2/2 (33.3)
Influenza1/1 (16.7)CSF neutrophil count increase9/5 (83.3)
Localised infection1/1 (16.7)CSF protein increase5/4 (66.7)
Sinusitis1/1 (16.7)CSF WBC increase7/5 (83.3)
Staphylococcal infection1/1 (16.7)Musculoskeletal disorders
Subcutaneous abscess1/1 (16.7)Arthralgia3/3 (50)
InjuriesJoint stiffness2/1 (16.7)
Joint injury2/2 (33.3)Nervous system disorders
Laboratory parametersDizziness3/3 (50)
Blood albumin decrease2/1 (16.7)Headache8/4 (66.7)
Blood creatine phosphokinase decrease4/3 (50)Respiratory disorders
Blood creatinine decrease7/5 (83.3)Oropharyngeal pain2/1 (16.7)
  • Single episodes of the following also occurred: neutropenia, thrombocytopenia, conjunctivitis allergic, lacrimation increased, vision blurred, abdominal pain, nausea, condition aggravated, procedural pain, blood albumin increased, blood alkaline phosphatase increased, blood chloride increased, blood creatine phosphatase increased, blood glucose increased, blood triglycerides increased, haematocrit decreased, haemoglobin decreased, heart rate increased, high-density lipoprotein decreased, platelet count decreased, platelet count increased, red blood cell count increased, costochondritis, memory impairment, sinus headache, amenorrhoea, cough, nasal congestion, acne, eczema, pityriasis rosea, rash.

  • CSF, cerebral spinal fluid; NOMID, neonatal-onset multisystem inflammatory disease; RBC, red blood cells; WBC, white blood cells.